TheraMicro

TheraMicro is a South Korean biotechnology company specializing in the development of therapeutics based on microbiome-derived extracellular vesicles (MDVs). Founded by experts from Seoul National University, the company leverages its proprietary platform to isolate and engineer vesicles from beneficial bacteria to treat inflammatory and autoimmune diseases. Their lead programs target conditions such as atopic dermatitis and psoriasis, with additional research into oncology applications. TheraMicro aims to harness the natural signaling capabilities of the microbiome to create a new class of targeted, low-toxicity biologic drugs. The company's technology focuses on the unique immunomodulatory properties of these vesicles, which can penetrate tissues more effectively than whole bacteria.